- Home
- CATX vs BBNX Comparison
CATX vs BBNX Comparison
Compare CATX & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | BBNX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.9M | 493.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CATX | BBNX |
|---|---|---|
| Price | $4.56 | $11.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $12.11 | ★ $23.80 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $8.80 |
| 52 Week High | $6.16 | $32.71 |
Technical Indicators
Market Signals| Indicator | CATX | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 48.95 |
| Support Level | $3.93 | $11.33 |
| Resistance Level | $4.63 | $11.92 |
| Average True Range (ATR) | 0.29 | 1.12 |
| MACD | 0.05 | 0.17 |
| Stochastic Oscillator | 62.80 | 56.26 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.